000132823 001__ 132823
000132823 005__ 20240229105034.0
000132823 0247_ $$2doi$$a10.1088/1752-7163/aab5be
000132823 0247_ $$2pmid$$apmid:29528036
000132823 0247_ $$2ISSN$$a1752-7155
000132823 0247_ $$2ISSN$$a1752-7163
000132823 0247_ $$2altmetric$$aaltmetric:35708936
000132823 037__ $$aDKFZ-2018-00467
000132823 041__ $$aeng
000132823 082__ $$a610
000132823 1001_ $$0P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aKrilaviciute, Agne$$b0$$eFirst author$$udkfz
000132823 245__ $$aPotential of non-invasive breath tests for preselecting individuals for invasive gastric cancer screening endoscopy.
000132823 260__ $$aBristol$$bIOP$$c2018
000132823 3367_ $$2DRIVER$$aarticle
000132823 3367_ $$2DataCite$$aOutput Types/Journal article
000132823 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659962808_8497
000132823 3367_ $$2BibTeX$$aARTICLE
000132823 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132823 3367_ $$00$$2EndNote$$aJournal Article
000132823 520__ $$aRegular screening for gastric cancer (GC) is based on invasive upper gastrointestinal endoscopy and is limited to few high-incidence countries. As GC is a major cause of cancer death worldwide, a non-invasive, simple screening test is of value. We assessed the prevalence of preclinical GC and the corresponding numbers needed to screen (NNS) to detect GC cases both without and with preselection using breath tests from the literature in various populations.Using age- and sex-specific GC incidence data and rates of transition from preclinical to clinical GC, we estimated the prevalences of preclinical GC worldwide in populations aged 50-74 years, and we evaluated the accuracy of breath testing for GC detection based on published studies. We then derived the expected positive predictive values for breath testing in populations with different preclinical GC prevalences.Four studies reporting the sensitivity and specificity of breath tests were identified, and summary estimates of 83% sensitivity and 91% specificity were derived by meta-analysis. The estimates of the overall prevalence of preclinical GC were <0.5% in men and <0.2% in women aged 50-74 years across different regions of the world. The positive predictive values, the prevalence among breath test positive people, were approximately nine-fold higher in all populations, resulting in an approximately nine-fold lower NNS to detect one GC case when breath tests were used for preselection for screening.Given the low prevalence of preclinical GC, non-invasive breath tests show promise for making screening more efficient. Further validation of breath tests and evidence on the rates of transition from preclinical to clinical GC are needed to validate the breath test approach.
000132823 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132823 588__ $$aDataset connected to CrossRef, PubMed,
000132823 7001_ $$0P:(DE-He78)908880209a64ea539ae8dc5fdb7e0a91$$aStock, Christian$$b1$$udkfz
000132823 7001_ $$aLeja, Marcis$$b2
000132823 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000132823 773__ $$0PERI:(DE-600)2381007-5$$a10.1088/1752-7163/aab5be$$gVol. 12, no. 3, p. 036009 -$$n3$$p036009 -$$tJournal of breath research$$v12$$x1752-7163$$y2018
000132823 909CO $$ooai:inrepo02.dkfz.de:132823$$pVDB
000132823 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132823 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908880209a64ea539ae8dc5fdb7e0a91$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132823 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132823 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132823 9141_ $$y2018
000132823 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132823 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132823 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132823 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ BREATH RES : 2015
000132823 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132823 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132823 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132823 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132823 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132823 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132823 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132823 980__ $$ajournal
000132823 980__ $$aVDB
000132823 980__ $$aI:(DE-He78)C070-20160331
000132823 980__ $$aI:(DE-He78)G110-20160331
000132823 980__ $$aI:(DE-He78)L101-20160331
000132823 980__ $$aUNRESTRICTED